NYSE - Delayed Quote • USD
Zoetis Inc. (ZTS)
At close: 4:00 PM EDT
After hours: 7:03 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 17 | 17 |
| Avg. Estimate | 1.35 | 1.51 | 5.8 | 6.45 |
| Low Estimate | 1.3 | 1.47 | 5.66 | 6.08 |
| High Estimate | 1.39 | 1.58 | 6.04 | 6.99 |
| Year Ago EPS | 1.31 | 1.41 | 5.32 | 5.8 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 16 | 16 |
| Avg. Estimate | 2.15B | 2.33B | 9.17B | 9.82B |
| Low Estimate | 2.11B | 2.3B | 9.12B | 9.6B |
| High Estimate | 2.18B | 2.35B | 9.25B | 10.16B |
| Year Ago Sales | 2.01B | 2.17B | 8.54B | 9.17B |
| Sales Growth (year/est) | 6.90% | 7.50% | 7.40% | 7.00% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 1.26 | 1.31 | 1.36 | 1.32 |
| EPS Actual | 1.31 | 1.41 | 1.36 | 1.24 |
| Difference | 0.05 | 0.1 | 0 | -0.08 |
| Surprise % | 4.00% | 7.60% | 0.00% | -6.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 1.35 | 1.51 | 5.8 | 6.45 |
| 7 Days Ago | 1.35 | 1.51 | 5.8 | 6.48 |
| 30 Days Ago | 1.36 | 1.51 | 5.8 | 6.48 |
| 60 Days Ago | 1.36 | 1.52 | 5.86 | 6.54 |
| 90 Days Ago | 1.4 | 1.54 | 6.04 | 6.74 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 3 | 1 | 2 | 1 |
Growth Estimates
| CURRENCY IN USD | ZTS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 3.10% | -- | -- | 1.60% |
| Next Qtr. | 7.10% | -- | -- | 10.50% |
| Current Year | 9.00% | -- | -- | 5.20% |
| Next Year | 11.20% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 9.73% | -- | -- | 11.22% |
| Past 5 Years (per annum) | 10.28% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | Piper Sandler: Overweight to Overweight | 4/16/2024 |
| Maintains | Stifel: Buy to Buy | 4/2/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 2/20/2024 |
| Maintains | Barclays: Overweight to Overweight | 2/14/2024 |
| Maintains | Goldman Sachs: Buy to Buy | 1/17/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 11/6/2023 |
Related Tickers
ITCI Intra-Cellular Therapies, Inc.
72.37
+0.51%
ELAN Elanco Animal Health Incorporated
12.95
-4.57%
VTRS Viatris Inc.
11.25
+1.17%
LNTH Lantheus Holdings, Inc.
63.81
+2.37%
CGC Canopy Growth Corporation
7.93
+1.28%
TEVA Teva Pharmaceutical Industries Limited
12.86
+0.63%
SXTC China SXT Pharmaceuticals, Inc.
1.0200
+3.03%
TLRY Tilray Brands, Inc.
1.7300
+0.58%
GTBIF Green Thumb Industries Inc.
12.37
-4.33%
TAK Takeda Pharmaceutical Company Limited
13.24
+0.61%